The earnings, however, didn't earn him bragging rights. Profits more than doubled on higher sales of the Vytorin and Zetia cholesterol - net income climbed to $750 million, or 45 cents a share, from $309 million, or 19 cents, a year earlier. But when excluding items related to the $14.4 billion Organon acquisition, Schering-Plough missed Wall Street forecasts of 30 cents a share.
Revenue jumped to $2.81 billion from $2.57 billion, thanks to new scrips for Vytorin, which combines Zetia with Merck's Zocor. While cheaper, generic copies of Zocor have been sold since June 2006, Vytorin sales are boosted by a $128 million ad campaign citing how the pill fights cholesterol in two ways and by studies comparing it with other branded meds, Bloomberg News notes.